Which pricing strategy is specifically associated with orphan drugs for rare diseases, often resulting in higher prices due to limited patient populations?

Pricing strategies in the pharmaceutical industry are complex and multifaceted, especially when it comes to specialized medications. Orphan drugs, which treat rare diseases affecting small populations, represent a unique segment of the medical product market with distinctive pricing challenges and regulatory frameworks. Test your knowledge about this fascinating intersection of medicine, product development, and pricing strategy!

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Value-based pricing, where pharmaceutical companies set prices based on the therapeutic benefit and demonstrated health outcomes of the medication
Premium pricing with recoupment model, where high prices are justified by R&D investments that must be recovered from a small patient population
Penetration pricing, where medications are initially priced low to gain market share before gradually increasing price points
Reference pricing, where prices are set according to the average cost of similar treatments in the same therapeutic category